TABLE 5

Physician-assessed response in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) according to subgroups based on the number of previous lines of treatment, the duration of previous treatment with crizotinib and dose reduction

Radiological tumour evaluationPrevious lines of treatmentDuration of previous crizotinib treatment#Dose reduction
≤2 lines (n=98)>2 lines (n=94)<Q1 (n=47)Q1−Q2 (n=47)Q2−Q3 (n=46)≥Q3 (n=49)With dose reduction (n=84)Without dose reduction (n=109)
Assessed response
 Evaluable subjects7276363135437475
 CR5 (6.9)3 (3.9)0 (0.0)4 (12.9)2 (5.7)2 (4.7)5 (6.8)3 (4.0)
 PR35 (48.6)35 (46.1)13 (36.1)12 (38.7)20 (57.1)23 (53.5)36 (48.6)34 (45.3)
 SD18 (25.0)15 (19.7)10 (27.8)5 (16.1)7 (20.0)10 (23.3)17 (23.0)17 (22.7)
 PD10 (13.9)9 (11.8)10 (27.8)3 (9.7)3 (8.6)3 (7.0)8 (10.8)11 (14.7)
 Not realised3 (4.2)13 (17.1)3 (8.3)5 (16.1)3 (8.6)5 (11.6)6 (8.1)10 (13.3)
 Not evaluable1 (1.4)1 (1.3)0 (0.0)2 (6.5)0 (0.0)0 (0.0)2 (2.7)0 (0.0)
 ORR40 (55.5)38 (50.0)13 (36.1)16 (51.6)22 (62.8)25 (58.2)41 (55.4)37 (49.3)
Treatment duration
 Subjects9190434543478399
 Duration months3.8 (0.4–23.0)3.7 (0.4–22.4)2.3 (0.4–15.9)3.0 (0.4–23.0)5.1 (0.4–19.9)7.6 (0.9–22.2)4.9 (0.4–22.2)2.7 (0.4–23.0)

Data are presented as n, n (%) or median (range). CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; ORR: overall response rate. #: <Q1 means <5 months of crizotinib, Q1–Q2 means 5 to <9.2 months of crizotinib, Q2–Q3 means 9.2 to <16 months of crizotinib >Q3 means >16 months of crizotinib. : dose reduction is <750 mg·day−1 of ceritinib or a temporary discontinuation in the first 6 months of treatment.